Damora Therapeutics (DMRA) Non-Current Assets (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Non-Current Assets came in at $42000.0 in Q1 2026, down 90.97% YoY from $465000.0 in Q1 2025, and down 59.62% on a QoQ basis from $104000.0 in Q4 2025.
Damora Therapeutics (DMRA) Non-Current Assets (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Non-Current Assets data on file, last reported at $42000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 90.97% year-over-year to $42000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 65.56% YoY) and the FY2025 annual result came in at $104000.0, down 68.67% from the prior year.
- Non-Current Assets declined to $42000.0 in Q1 2026, from $104000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $11.9 million in Q1 2022 to a low of $42000.0 in Q1 2026.
- A 5-year average of $3.9 million and a median of $2.1 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets fell 23.32% — and 2026, when it sank 90.97%.
- Tracing DMRA's Non-Current Assets over 5 years: stood at $9.3 million in 2022, then slumped by 84.36% to $1.5 million in 2023, then slumped by 77.15% to $332000.0 in 2024, then plunged by 68.67% to $104000.0 in 2025, then tumbled by 59.62% to $42000.0 in 2026.
- The last three Non-Current Assets figures came in at $42000.0 (Q1 2026), $104000.0 (Q4 2025), and $936000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36,000.00 |
| Mar 31, 2026 | 42,000.00 |
| Dec 31, 2025 | 104,000.00 |
| Sep 30, 2025 | 936,000.00 |
| Jun 30, 2025 | 664,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Sep 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Mar 31, 2024 | 1.98 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 7.53 Mn |
| Dec 31, 2022 | 9.29 Mn |
| Sep 30, 2022 | 10.83 Mn |
| Jun 30, 2022 | 10.66 Mn |
| Mar 31, 2022 | 11.90 Mn |
| Dec 31, 2021 | 12.11 Mn |
| Sep 30, 2021 | 28.87 Mn |